{"disease":{"id":"opioid-induced-constipation","name":"opioid induced constipation"},"drugs":{"marketed":[{"drug_id":"methylnaltrexone","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Relistor","generic_name":"METHYLNALTREXONE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":69,"revenue":"400","mechanism":"Relistor works by blocking opioid receptors in the gut to alleviate constipation."},{"drug_id":"naldemedine","indication_name":"Opioid-induced constipation (OIC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symproic","generic_name":"NALDEMEDINE","company_name":"Bdsi","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":75,"revenue":null,"mechanism":"Symproic works by blocking the mu-type opioid receptor, which is responsible for slowing down bowel movements."},{"drug_id":"naldemedine","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symproic","generic_name":"NALDEMEDINE","company_name":"Bdsi","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":75,"revenue":null,"mechanism":"Symproic works by blocking the mu-type opioid receptor, which is responsible for slowing down bowel movements."},{"drug_id":"naltrexon","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naltrexon","company_name":"Institute of Liver and Biliary Sciences, India","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"movantik","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Movantik","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"naloxegol","indication_name":"Therapeutic opioid induced constipation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Movantik","generic_name":"NALOXEGOL","company_name":"Averitas","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Opioid Antagonist","quality_score":65,"revenue":null,"mechanism":"Movantik works by blocking the mu-type opioid receptor, which is responsible for the constipating effects of opioids."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03720613","title":"Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation","phase":"","overall_status":"RECRUITING","enrollment_count":34532,"lead_sponsor_name":"BioDelivery Sciences International","has_results":false},{"nct_id":"NCT02813356","title":"Naloxegol US PMR CV Safety.","phase":"","overall_status":"UNKNOWN","enrollment_count":8800,"lead_sponsor_name":"Valinor Pharma LLC","has_results":false},{"nct_id":"NCT01696643","title":"Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1407,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01965652","title":"Long Term Safety of Naldemedine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1246,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT05149833","title":"European Study of Opioid Induced Constipation","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"University of Dublin, Trinity College","has_results":false},{"nct_id":"NCT04350112","title":"Study of Opioid-Induced Constipation 1 Project","phase":"","overall_status":"COMPLETED","enrollment_count":1007,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT01186770","title":"A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":804,"lead_sponsor_name":"Bausch Health Americas, Inc.","has_results":true},{"nct_id":"NCT01993940","title":"Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT01965158","title":"Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":547,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT03060512","title":"To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":276,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02270983","title":"Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT01443403","title":"A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT03638440","title":"Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.","phase":"","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Kyowa Kirin Pharmaceutical Development Ltd","has_results":false},{"nct_id":"NCT01117051","title":"Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":174,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01207427","title":"Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04173858","title":"Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Kyowa Kirin Farmacéutica S.L.U.","has_results":false},{"nct_id":"NCT07038551","title":"Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"International University of Health and Welfare","has_results":false},{"nct_id":"NCT04876508","title":"The Efficacy of Acupressure in Managing Opioid-induced Constipation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Istanbul Aydın University","has_results":false},{"nct_id":"NCT07231796","title":"Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Professor Monique A. H. Steegers","has_results":false},{"nct_id":"NCT03797586","title":"Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","has_results":true},{"nct_id":"NCT04404933","title":"Study of Opioid-Induced Constipation 2 Project","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT01109511","title":"A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Ullevaal University Hospital","has_results":false},{"nct_id":"NCT03355807","title":"Use of MgSO4 for Pain After Bariatric Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Yeditepe University Hospital","has_results":false},{"nct_id":"NCT01901302","title":"Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":61,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01901328","title":"Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":49,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT01901341","title":"The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":44,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT00640146","title":"Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Bausch Health Americas, Inc.","has_results":true},{"nct_id":"NCT01368562","title":"Compassionate Use Study of Methylnaltrexone","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Bausch Health Americas, Inc.","has_results":true},{"nct_id":"NCT05588323","title":"Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT06385561","title":"The Influence of Tramadol on Opioid-induced Bowel Dysfunction","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Asbjørn Mohr Drewes","has_results":false},{"nct_id":"NCT05770960","title":"Colonic Motor Patterns in Healthy Volunteers","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT05133076","title":"Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"BioGaia Pharma AB","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}